Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis (HEMOCOEUR)

October 18, 2017 updated by: Rennes University Hospital

Estimation of Myocardial Iron Overload by 3 Tesla MRI and Cardiac Functional Consequences in Patients With HFE Hereditary Haemochromatosis. Pilot Study

Hereditary haemochromatosis (HHC) is a frequent disease in Brittany (5 to 7‰), responsible first for biological disorder in blood iron parameters and minor clinical disorders, before evolving to potential life-threatening consequences such as diabetes, liver cirrhosis and congestive heart failure.

The improvement of screening and treatments made those severe affections rare enough not to evaluate myocardial iron overload a systematic part of the starting check-up. Nonetheless this myocardial iron overload might have severe implications on cardiac function on a long term basis.

A single trial was conducted on limited number of patients with 1.5 Tesla MRI, which showed a myocardial iron overload (defined by a myocardium T2* value <20ms) in 19% of the subjects.

The main objective of this study is to precisely estimate cardiac iron overload in treatment naive patients with newly diagnosed HFE hereditary haemochromatosis with a 3 Tesla MRI, more sensitive than the 1.5 Tesla one, in order to later appreciate its correlation with cardiac morbidity in HHC.

Study Overview

Detailed Description

Since the wide use of phlebotomy was implemented the incidence of congestive heart failure in HHC became quite low. As such, the interest towards the initial diagnosis and cardiological follow-up has been lesser. A subclinical myocardial iron overload can nevertheless exist and eventually lead to functional consequences in the medium and long term if neglected, even evolve into heart failure and preserved ejection fraction.

The expected aftermath of this study is :

  • The estimation of the frequency of myocardial iron overload measured by 3 Tesla MRI in patient with HFE hereditary haemochromatosis;
  • The assessment of its consequences on heart function;
  • The appreciation of a cardiological assessment strategy in patients with HFE hereditary haemochromatosis.

Study Type

Interventional

Enrollment (Actual)

66

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Rennes, France, 35000
        • Rennes University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Patients :

  • Adults older than 18 ;
  • Newly diagnosed with HFE hereditary haemochromatosis by genetic testing (homozygous for the C283Y mutation on HFE gene);
  • Treatment-naive;
  • Showing a ferritin level higher than 200µg/l for women and higher than 300µg/L for men;
  • Affiliated to French Social Security;
  • Having given a written informed consent.

Healthy volunteers:

  • Adults older than 18;
  • Presenting all the following criterions:

    • Normal cardiovascular physical examination: no signs of cardiac insufficiency, no pathological cardiac murmur, normal EKG (regular sinus rhythm, no high degree AV nor ventricular blocks, no rhythm anomaly),
    • Body Mass Index <27 kg/m²,
    • Normal routine blood biology (blood count, MCV, serum iron, ferritin, transferrin saturation);
  • Affiliated to French Social Security;
  • Having given a written informed consent.

Exclusion Criteria:

Patients :

MRI-related criterions :

  • Cardiac pacemaker or implanted defibrillator ;
  • Non MRI-compatible prosthetic cardiac valve;
  • Non MRI-compatible clips/stents/coils/etc.;
  • Cochlear implant;
  • Peripheral or neuronal stimulator;
  • Intra-ocular or brain metallic foreign bodies , foreign body in the eyes' vicinity, shrapnel or firearm wound;
  • Less than 4 weeks-old stents, less than 6 weeks-old osteosynthesis materials;
  • Claustrophobia;
  • Pumps, tattoos, permanent makeup, intrauterine device, patches;
  • Non-removable metallic or magnetic material in the vicinity of the analysed field.

Other criterions :

  • Haemodynamic instability / Acute respiratory insufficiency / Altered general status / Need for continuous monitoring incompatible wih MRI confines;
  • Pregnancy, breast feeding;
  • History of blood transfusion or iron supplementation;
  • Blood donation in the last 3 months;
  • Infection in the 7 days prior to the first visit;
  • Stay in altitude (>1500m) in the past 2 months;
  • Adults under legal protective regimen or deprived of liberty.

Healthy volunteers

  • Alcohol abuse (>20g per day for women, >30g per day for men);
  • Active tobacco intoxication or smoking cessation in the 6 last months;
  • Personal cardiovascular medical history;
  • Cardiovascular functional signs.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patients with HFE hereditary haemochromatosis

The patients (40) will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions.

Then will be performed :

  • An electrocardiogram
  • Blood tests : iron and cardiac markers (serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP), beta-hCG if needed, serum bank
  • A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)
  • A 3Tesla abdominal MRI
  • An echocardiography at rest.
Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
Beta-hCG
Transthoracic echocardiograph
Experimental: Healthy volunteers

The healthy volunteers (10 men and 10 women) will undergo :

  • A urinary pregnancy test (if applicable)
  • A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)
  • An echocardiography at rest.
Transthoracic echocardiograph

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Myocardial T2* values in haemochromatosis compared to healthy volunteers
Time Frame: Day 1
Assessment of the percentage rate of patients presenting a lower T2* value than the baseline defined by the mean of T2* values measured in healthy volunteers with a 1 standard deviation margin.
Day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean T2 values in healthy volunteers and patients with HFE-related haemochromatosis
Time Frame: Day 1
Comparison of the mean T2 values in healthy volunteers and patients with HFE-related haemochromatosis
Day 1
Echocardiographic parameters of systolic and diastolic functions and myocardial deformation
Time Frame: Day 1
Day 1
Myocardial T2 and T2* values in both groups
Time Frame: Day 1
Day 1
Liver T2/T2* values
Time Frame: Day 1
Correlation between liver T2/T2* and myocardial T2/T2*
Day 1
Pancreas T2/T2* values
Time Frame: Day 1
Correlation between pancreas T2/T2* and myocardial T2/T2*
Day 1
Spleen T2/T2* values
Time Frame: Day 1
Correlation between spleen T2/T2* and myocardial T2/T2*
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Erwan DONAL, MD, PhD, Rennes University Hospital - Service de cardiologie et maladies vasculaires

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 5, 2014

Primary Completion (Actual)

October 18, 2017

Study Completion (Actual)

October 18, 2017

Study Registration Dates

First Submitted

March 21, 2014

First Submitted That Met QC Criteria

March 27, 2014

First Posted (Estimate)

March 28, 2014

Study Record Updates

Last Update Posted (Actual)

October 20, 2017

Last Update Submitted That Met QC Criteria

October 18, 2017

Last Verified

October 1, 2017

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myocardial Iron Overload

Clinical Trials on 3Tesla cardiac MRI

3
Subscribe